A novel pyrazole-containing indolizine derivative suppresses NF-κB activation and protects against TNBS-induced colitis via a PPAR-γ-dependent pathway

Biochemical Pharmacology

Volumn 135, Issue , 2017, Pages 126-138

  Fu, Yong ^a   Ma, Junting ^a   Shi, Xiafei ^a   Song, Xiang Yun ^b   Yang, Yaping ^a   Xiao, Shuke ^a   Li, Jiahuang ^a   Gu, Wei Jin ^b   Huang, Zhen ^a   Zhang, Junfeng ^a   Chen, Jiangning ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING NORMAL UNIVERSITY   (China)

Author keywords

Colitis; NF B; PPAR ; Pyrazole containing indolizine derivatives

Indexed keywords

3 (3,5 DIMETHYL 1H PYRAZOLE 1 CARBONYL) 5 METHYLINDOLIZINE 1 CARBONITRILE; 3 (3,5 DIMETHYL 1H PYRAZOLE 1 CARBONYL) 5,7 DIMETHYLINDOLIZINE 1 CARBONITRILE; 3 (3,5 DIMETHYL 1H PYRAZOLE 1 CARBONYL) 7 METHYLINDOLIZINE 1 CARBONITRILE; 3 (3,5 DIMETHYL 1H PYRAZOLE 1 CARBONYL)INDOLIZINE 1 CARBONITRILE; 3 (3,5 DIMETHYL 1H PYRAZOLE 1 CARBONYL)PYRROLO[2,1 A]ISOQUINOLINE 1 CARBONITRILE; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; AMINOSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INDOLIZINE DERIVATIVE; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; NUCLEAR PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTECTIVE AGENT; PYRAZOLE DERIVATIVE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; INDOLIZINE; PYRAZOLE; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; COLON TISSUE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE ACTIVITY; DRUG SYNTHESIS; ENZYME ACTIVITY; FEMALE; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY CELL; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRINITROBENZENE SULFONIC ACID-INDUCED COLITIS; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMICALLY INDUCED; COLITIS; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM;

ANILIDES; ANIMALS; COLITIS; FEMALE; INDOLIZINES; MICE; MICE, INBRED BALB C; MICE, INBRED ICR; NF-KAPPA B; PPAR GAMMA; PROTECTIVE AGENTS; PYRAZOLES; TRINITROBENZENESULFONIC ACID;

EID: 85016578248     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2017.03.013     Document Type: Article

References (41)

1. Khor, B., Gardet, A., Xavier, R.J., Genetics and pathogenesis of inflammatory bowel disease. Nature 474:7351 (2011), 307–317.
2. Kappelman, M.D., Moore, K.R., Allen, J.K., Cook, S.F., Recent trends in the prevalence of Crohn's disease and ulcerative colitis in a commercially insured US population. Dig. Dis. Sci. 58:2 (2013), 519–525.
3. Zuo, L., Huang, Z., Dong, L., Xu, L., Zhu, Y.A., Zeng, K., Zhang, C., Chen, J., Zhang, J., Targeting delivery of anti-TNFα oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut 59:4 (2010), 470–479.
4. Rogler, G., Brand, K., Vogl, D., Page, S., Hofmeister, R., Andus, T., Knuechel, R., Baeuerle, P.A., Schölmerich, J., Gross, V., Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115:2 (1998), 357–369.
5. Gersemann, M., Wehkamp, J., Stange, E.F., Innate immune dysfunction in inflammatory bowel disease. J. Intern. Med. 271:5 (2012), 421–428.
6. Shah, Y.M., Morimura, K., Gonzalez, F.J., Expression of peroxisome proliferator-activated receptor-γ in macrophage suppresses experimentally-induced colitis. Am. J. Physiol. Gastrointest. liver Physiol. 292:2 (2007), G657–G666.
7. Wang, X., Sun, Y., Zhao, Y., Ding, Y., Zhang, X., Kong, L., Li, Z., Guo, Q., Zhao, L., Oroxyloside prevents dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB pathway through PPARγ activation. Biochem. Pharmacol. 106 (2016), 70–81.
8. Choo, J., Lee, Y., Yan, X.J., Noh, T.H., Kim, S.J., Son, S., Pothoulakis, C., Moon, H.R., Jung, J.H., Im, E., A Novel Peroxisome Proliferator-activated Receptor (PPAR)γ Agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate Exerts Anti-Inflammatory Effects in Colitis. J. Biol. Chem. 290:42 (2015), 25609–25619.
9. Sánchez-Hidalgo, M., Martín, A.R., Villegas, I., Alarcón De La Lastra, C., Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem. Pharmacol. 69:12 (2005), 1733–1744.
10. Torres, J., Danese, S., Colombel, J.-F., New therapeutic avenues in ulcerative colitis: thinking out of the box. Gut 62:11 (2013), 1642–1652.
11. Dawood, K.M., Abdel-Gawad, H., Ellithey, M., Mohamed, H.A., Hegazi, B., Synthesis, anticonvulsant, and anti-inflammatory activities of some new benzofuran-based heterocycles. Arch. Pharm. 339:3 (2006), 133–140.
12. Nayak, P.S., Narayana, B., Sarojini, B.K., Fernades, J., Bharath, B.R., Madhu, L.N., Synthesis, molecular docking and biological evaluation of novel bis-pyrazole derivatives for analgesic, anti-inflammatory and antimicrobial activities. Med. Chem. Res. 24:12 (2015), 4191–4206.
13. Gu, W.-J., Xie, W.-L., Wang, T.-T., 1-[(3,5-Dimethyl-1H-pyrazol-1-yl)carbonyl]- 5-methylindolizine-3-carbonitrile. Acta Crystallogr. Sect. E: Struct. Rep. Online, 68(Pt 12), 2012 o3399-o3399.
14. Huang, Z., Ma, J., Chen, M., Jiang, H., Fu, Y., Gan, J., Dong, L., Zhang, J., Chen, J., Dual TNF-α/IL-12p40 interference as a strategy to protect against colitis based on miR-16 precursors with macrophage targeting vectors. Mol. Ther. 23:10 (2015), 1611–1621.
15. Neurath, M.F., Fuss, I., Kelsall, B.L., Stüber, E., Strober, W., Antibodies to interleukin 12 abrogate established experimental colitis in mice. J. Exp. Med. 182:5 (1995), 1281–1290.
16. Bento, A.F., Marcon, R., Dutra, R.C., Claudino, R.F., Cola, M., Pereira Leite, D.F., Calixto, J.B., β-Caryophyllene inhibits dextran sulfate sodium-induced colitis in mice through cb2 receptor activation and PPARγ pathway. Am. J. Pathol. 178:3 (2011), 1153–1166.
17. Alex, P., Zachos, N.C., Nguyen, T., Gonzales, L., Chen, T.E., Conklin, L.S., Centola, M., Li, X., Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm. Bowel Dis. 15:3 (2009), 341–352.
18. Nakajima, A., Wada, K., Miki, H., Kubota, N., Nakajima, N., Terauchi, Y., Ohnishi, S., Saubermann, L.J., Kadowaki, T., Blumberg, R.S., Nagai, R., Matsuhashi, N., Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120:2 (2001), 460–469.
19. Wirtz, S., Neufert, C., Weigmann, B., Neurath, M.F., Chemically induced mouse models of intestinal inflammation. Nat. Protocols 2:3 (2007), 541–546.
20. Singh, G.S., Mmatli, E.E., Recent progress in synthesis and bioactivity studies of indolizines. Eur. J. Med. Chem. 46:11 (2011), 5237–5257.
21. Hagishita, S., Yamada, M., Shirahase, K., Okada, T., Murakami, Y., Ito, Y., Matsuura, T., Wada, M., Kato, T., Ueno, M., Chikazawa, Y., Yamada, K., Ono, T., Teshirogi, I., Ohtani, M., Potent inhibitors of secretory phospholipase A2: synthesis and inhibitory activities of indolizine and indene derivatives. J. Med. Chem. 39:19 (1996), 3636–3658.
22. Shaveta, A., Singh, M., Kaur, S., Sharma, R., Bhatti Singh, P., Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: Identification of a lead for anti-inflammatory drug. Eur. J. Med. Chem. 77 (2014), 185–192.
23. Lee, Y., Kim, W., Hong, S., Park, H., Yum, S., Yoon, J.-H., Jung, Y., Colon-targeted celecoxib ameliorates TNBS-induced rat colitis: a potential pharmacologic mechanism and therapeutic advantages. Eur. J. Pharmacol. 726 (2014), 49–56.
24. Dubuquoy, L., Rousseaux, C., Thuru, X., Peyrin-Biroulet, L., Romano, O., Chavatte, P., Chamaillard, M., Desreumaux, P., PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 55:9 (2006), 1341–1349.
25. Annese, V., Rogai, F., Settesoldi, A., Bagnoli, S., PPARγ in inflammatory bowel disease. PPAR Res., 2012, 2012, 9.
26. Yang, Y., Yan, H., Jing, M., Zhang, Z., Zhang, G., Sun, Y., Shan, L., Yu, P., Wang, Y., Xu, L., Andrographolide derivative AL-1 ameliorates TNBS-induced colitis in mice: involvement of NF-кB and PPAR-γ signaling pathways. Sci. Rep., 6, 2016, 29716.
27. Pedersen, G., Brynskov, J., Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-[gamma] activity. Am. J. Gastroenterol. 105:7 (2010), 1595–1603.
28. Buckingham, R.E., Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 33:2 (2005), 167–170.
29. Zhang, M., Deng, C., Zheng, J., Xia, J., Sheng, D., Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma. Int. Immunopharmacol. 6:8 (2006), 1233–1242.
30. Adachi, M., Kurotani, R., Morimura, K., Shah, Y., Sanford, M., Madison, B.B., Gumucio, D.L., Marin, H.E., Peters, J.M., Young, H.A., Gonzalez, F.J., Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55:8 (2006), 1104–1113.
31. Bassaganya-Riera, J., Reynolds, K., Martino-Catt, S., Cui, Y., Hennighausen, L., Gonzalez, F., Rohrer, J., Benninghoff, A.U., Hontecillas, R., Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127:3 (2004), 777–791.
32. Katayama, K., Wada, K., Nakajima, A., Mizuguchi, H., Hayakawa, T., Nakagawa, S., Kadowaki, T., Nagai, R., Kamisaki, Y., Blumberg, R.S., Mayumi, T., A novel PPARγ gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 124:5 (2003), 1315–1324.
33. Andresen, L., Jørgensen, V.L., Perner, A., Hansen, A., Eugen-Olsen, J., Rask-Madsen, J., Activation of nuclear factor κB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 54:4 (2005), 503–509.
34. Hirata, I., Yasumoto, S., Toshina, K., Inoue, T., Nishikawa, T., Murano, N., Murano, M., Wang, F.Y., Katsu, K., Evaluation of the effect of pyrrolidine dithiocarbamate in suppressing inflammation in mice with dextran sodium sulfate-induced colitis. World J. Gastroenterol. 13:11 (2007), 1666–1671.
35. Watanabe, N., Ikuta, K., Okazaki, K., Nakase, H., Tabata, Y., Matsuura, M., Tamaki, H., Kawanami, C., Honjo, T., Chiba, T., Elimination of local macrophages in intestine prevents chronic colitis in interleukin-10-deficient mice. Dig. Dis. Sci. 48:2 (2003), 408–414.
36. Lehrke, M., Lazar, M.A., The many faces of PPARγ. Cell 123:6 (2005), 993–999.
37. Hou, Y., Moreau, F., Chadee, K., PPARγ is an E3 ligase that induces the degradation of NFκB/p65. Nat. Commun., 3, 2012, 1300.
38. Kelly, D., Campbell, J.I., King, T.P., Grant, G., Jansson, E.A., Coutts, A.G.P., Pettersson, S., Conway, S., Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPAR-[gamma] and RelA. Nat. Immunol. 5:1 (2004), 104–112.
39. Lee, H.W., Lee, C.G., Rhee, D.K., Um, S.H., Pyo, S., Sinigrin inhibits production of inflammatory mediators by suppressing NF-kappaB/MAPK pathways or NLRP3 inflammasome activation in macrophages. Int. Immunopharmacol. 45 (2017), 163–173.
40. Adachi, M., Kurotani, R., Morimura, K., Shah, Y., Sanford, M., Madison, B.B., Gumucio, D.L., Marin, H.E., Peters, J.M., Young, H.A., Gonzalez, F.J., Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55:8 (2006), 1104–1113.
41. Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefebvre, P., Romano, O., Auwerx, J., Metzger, D., Wahli, W., Desvergne, B., Naccari, G.C., Chavatte, P., Farce, A., Bulois, P., Cortot, A., Colombel, J.F., Desreumaux, P., Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator–activated receptor-γ. J. Exp. Med. 201:8 (2005), 1205–1215.